SCHEMBL1709617

SCHEMBL1709617

CCN(CC)CCCS(=O)(=O)N[C@H](CCC1CCCCC1)c1nc(CO)n(C)n1

nearest known ligand 0.32

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1709586 0.89 BMP1 (0.31) GHSR
SCHEMBL10121990 0.88 CCR5 (0.33)
SCHEMBL1709582 0.88 BMP1 (0.30)
SCHEMBL10122140 0.87 GHSR (0.31) GHSR
SCHEMBL1709726 0.87 BCHE (0.33) GHSR
SCHEMBL10121988 0.87 CTSD (0.32)
SCHEMBL10122144 0.86
SCHEMBL10122135 0.85 GHSR (0.30) GHSR
SCHEMBL1709721 0.84 GHSR (0.40) GHSR
SCHEMBL1709581 0.82 CASP1 (0.40) GHSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088747-A1 SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF ELIXIR PHARMACEUTICALS, INC. 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088747-A1 SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF GHSR, GHRHR, STS GHSR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.